OTC: PHMMF - Pharma Mar, S.A.

Altı ay boyunca karlılık: +63.3%
Temettü getirisi: +2.09%
Sektör: Healthcare

Promosyon programı Pharma Mar, S.A.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.

daha fazla ayrıntı
The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

ISIN ES0169501022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.09
Дивиденд ао 0.6364
Сайт https://www.pharmamar.com
Цена ао 102.08
Günlük fiyat değişimi: 0% (88.183)
Haftalık fiyat değişimi: -13.61% (102.08)
Aylık fiyat değişimi: -7.94% (95.79)
3 ayda fiyat değişimi: +8.77% (81.07)
Altı ayda fiyat değişimi: +63.3% (54)
Yıllık fiyat değişimi: +201.07% (29.29)
3 yılda fiyat değişimi: +2.54% (86)
5 yılda fiyat değişimi: +6 555.32% (1.325)
Yılbaşından bu yana fiyat değişimi: +8.77% (81.07)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 7.83 1
P/BV 6.57 1
P/E 52.4 3
EV/EBITDA 1809.69 1
Toplam: 2.88

Yeterlik

İsim Anlam Seviye
ROA, % 7.94 2
ROE, % 13.63 4
Toplam: 1.83

Temettüler

İsim Anlam Seviye
Div yield, % 2.09 5.23
DSI 0.9286 9.29
Toplam: 4.94

Görev

İsim Anlam Seviye
Debt/EBITDA 115.42 0
Toplam: 7.2

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -20.65 0
karlılık Ebitda, % -144.64 0
karlılık EPS, % -75.71 0
Toplam: 0
Daha fazla ayrıntı

Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Legato Capital Management LLC 3481 0.02



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Jose Maria Fernandez Sousa-Faro Ph.D. Founder, Executive Chairman, CEO & President 320.14k
Mr. Pedro Francisco Fernandez Puentes Executive Vice-Chairman 135.03k
Mr. Juan Carlos-Torres Carretero Founder N/A 1949 (76 yıllar)
Ms. María Luisa de Francia Caballero Chief Financial Officer N/A
Mr. José Luis Moreno Martinez-Losa Head of Capital Markets & Investor Relations N/A
Mr. Juan Gomez Pulido General Counsel & Secretary of the Board of Directors N/A
Ms. Sandra Llamera Sanchez Global Compliance Head N/A
Ms. Lara Vadillo Communication Director N/A
Ms. Belén Sopesén Veramendi Ph.D. Director of Corporate Development N/A
Mr. Luis Rupérez Cuenca Director of Human Resources & IT N/A

Adres: Spain, Madrid, Avenida de los Reyes. 1 - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.pharmamar.com